Cancer Institute– A national cancer institute
designated cancer center

Philip A. Pizzo, M.D.

Back to Profile

Publication Details

  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.

    Mueller BU, Nelson RP, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, Wood LV, Zeichner S, Katz TT, Higham C, Aker D, Edgerly M, Jarosinski P, Serchuck L, Whitcup SM, Pizzuti D, Pizzo PA. Pediatrics. 1998; 101 (3 Pt 1): 335-43

    Ritonavir, a potent antiretroviral protease inhibitor, has been approved for the treatment of adults and children with human immunodeficiency virus (HIV) infection. In a phase I/II study, we assessed the safety, tolerability, and pharmacokinetic profile of the oral solution of ritonavir in HIV-infected children and studied the preliminary antiviral and clinical effects.

    PubMedID: 9480994

Stanford Medicine Resources:

Footer Links: